Myasthenia Gravis
NEJM 375:2570-2581, Gilhus, N.E.,et al, 2016
Intensive Care of the Myasthenic Patient
Neurol 48 (Suppl 5) :S70-S75997., Mayer,S.A., 1997
Chronic Immunotherapy for Myasthenia Gravis
www.UptoDate.Com, Bird,S.J., 2024
An 8-Year-Old with Acute Onset Ataxia
Neurol 99:305-310, McLaren, J.R.,et al, 2022
Myasthenic Crisis Demanding Mechanical Ventilation
Neurol 94:e299-e313, Neumann, B.,et al, 2020
Spasms and Myoclonus in a Young Woman with Hashimoto Thyroiditis
JAMA Neurol 77:650-651, Shen, D.,et al, 2020
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Clinical Reasoning: A 49-year-old man with Progressive Numbness, Weakness, and Evidence of Leptomeningeal Enhancement
Neurol 90:e90-e93, Lovett, A.,et al, 2018
Clinical Pathologic Conference, West Nile Virus Encephalitis
NEJM 377:1878-1886, Case 34-2017, 2017
International Consensus Guidance for Management of Myasthenia Gravis
Neurol 87:419-425, Sanders, D.B.,et al, 2016
Paraparetic Guillain-Barre Syndrome
Neurol 82:1984-1989, Van Den Berg, B.,et al, 2014
Evidence-based Guideline: Intravenous Immunoglobulin in the Treatment of Neuromascular Disorders
Neurol 78:1009-1015, Patwa,H.S.,et al, 2012
Comparison of IVIg and PLEX in patients with myasthenia gravis
Neurol 76:2017-2023, Barth, D.,et al, 2011
Clinical Reasoning: A 34-year-old man with recurrent limb weakness
Neurol 77:e68-e72, Karam, C.,et al, 2011
Diagnosis and Management of the Antiphospholipid Syndrome
BMJ 340:1125-1132, Cohen,D., et al, 2010
Comparative Analysis of Therapeutic Options Used for Myasthenia Gravis
Ann Neurol 68:797-805, Mandawat,A.,et al, 2010
Incidence and Mortality Rates of Myasthenia Gravis and Myasthenic Crisis in US Hospitals
Neurol 72:1548-1554, Alshekhlee,A.,et al, 2009
Long-Term Course of Demyelinating Neuropathies Occurring During Tumor Necrosis Factor-a-Blocker Therapy
JAMA Neurol 66:490-497, Lozeron, P.,et al, 2009
IV Immunoglobulin in Patients With Myasthenia Gravis
Neurol 68:837-841,803, Zinman,L., et al, 2007
Classifications and Treatment Responses in Chronic Immune-Mediated Demyelinating Polyneuropathy
Neurol 68:1622-1629, Tackenberg,B.,et al, 2007
Multifocal Motor Neuropathy: The Diagnostic Spectrum and Response to Treatment
Neurol 69:1680-1687, Slee,M.,et al, 2007
Clinicopath Conf., Multifocal Motor Neuropathy With Conduction Block
NEJM 357: 2707-2715, Case 40-2007, 2007
Childhood-onset Multifocal Motor Neuropathy with Conduction Blocks
Neurol 66:922-924, Moroni,I.,et al, 2006
Clinical and Electrophysiologic Correlates of IVIg Responsiveness in CIDP
Neurol 64:1471-1475, Iijima,M.,et al, 2005
Treatment of Myasthenia Gravis Exacerbation with Intravenous Immunoglobulin
Arch Neurol 62:1689-1693, Gajdos,P.,et al, 2005
Guillain-Barre Syndrome
Lancet 366:1653-1666, Hughes,R.C. &Comblath,D.R., 2005
Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases
JAMA 291:2367-2375, Dalakas,M.C., 2004
Management of Myasthenia Gravis
Semin Neurol 24:41-48, Saperstein,D.S. &Barohn,R.J., 2004
Clinicopath Conf., Chronic Inflammatory Demyelinating Polyneuropathy
NEJM 348:735-743, Case 6-2003, 2003
Treatment of Autoimmune Myasthenia Gravis
Neurol 61:1652-1661, Richman,D.P. & Agius,M.A., 2003
Worsening of Multifocal Motor Neuropathy During Pregnancy
Neurol 59:139-141, Chaudhry,V.,et al, 2002
Multifocal Motor Neuropathy Improved by IVIg
Neurol 55:1256-1262,1246, Federico,P.,et al, 2000
Plasma Exchange Versus Intravenous Immunoglobulin Treatment in Myasthenic Crisis
Neurol 52:629-632, Qureshi,A.I.,et al, 1999
Course and Treatment of Myasthenia Gravis During Pregnancy
Neurol 52:447-452, Batocchi,A.P.,et al, 1999
Intravenous Immunoglobulin Treatment in Neurologic Disorders
Arch Neurol 56:1025-1027,1032, Sorensen,P.S., 1999
Is the Routine Use of Intravenous Immunoglobulin Treatment in Neurologic Disorders Justified?
Arch Neurol 56:1028-1032, Karussis,D.&Abramsky,O., 1999
Intravenous Immunoglobulin in the Treatment of Autoimmune Neuromuscular Diseases:Present Status and Practical Therapeutic Guidelines
Muscle & Nerve 22:1479-1497, Dalakas,M.C., 1999
CIDP:Clinical Features & Responses to Trtm in 67 Consecutive Pts with/without a Monoclonal Gammopathy
Neurol 48:321-328, Gorson,K.G.,et al, 1997
Treatment of Acquired Myasthenia Gravis
Neurol 48 (Suppl 5) :S46-S51997., Massey,J.M., 1997
Clinical Trial of Plasma Exchange and High-dose Intravenous Immunoglobulin in Myasthenia Gravis
Ann Neurol 41:789-796, Gajdos,P.,et al, 1997
Multifocal Motor Neuropathy with Conduction Block and Campylobacter Jejuni
Neurol 46:562-563, White,J.R.,et al, 1996
Intravenous Immunoglobulin Treatment of Neurological Disease
JNNP 60:359-361, Otten,A.,et al, 1996
Multifocal Motor Neuropathy
JNNP 60:599-603, Nobile-Orazio,E., 1996
A Controlled Study of Intravenous Immunoglobulin in Demyelinating Neuropathy with IgM Gammopathy
Ann Neurol 40:792-795, Dalakas,M.C.,et al, 1996
Common Variable Immunodeficiency and Inclusion Body Myositis:A Distinct Myopathy Mediated by Natural Killer Cells
Ann Neurol 37:806-810, Dalakas,M.C.&Illa,I., 1995
Improvement of Multifocal Motor Neuropathy During Long-Term Weekly Treatment with Human Immunoglobulin
Neurol 45:987-988, van den Berg,L.H.,et al, 1995
Multifocal Motor Neuropathy with Conduction Block:A Study of 24 Patients
JNNP 59:38-44, Bouche,P.,et al, 1995
Successful Treatment of Neuropathies in Patients with Diabetes Mellitus
Arch Neurol 52:1053-1061, Krendel,D.A.,et al, 1995
Lambert-Eaton Myasthenic Syndrome:Clinical Diagnosis,Immune-Mediated Mechanisms,and Update on Therapies
Ann Neurol 37:S63-S73, Sanders,D.B., 1995